Expressing:Article Title: Drug and Device News
Article Snippet: Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) , Renova Therapeutics , Urocortin hormone , In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less. 10.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) Renova Therapeutics Urocortin hormone In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Ad5.hAC6 (RT-100) , Renova Therapeutics , Gene therapy , In a 56-patient, phase II trial, a single dose of RT-100 increased left ventricular peak and ejection fraction compared with placebo at 4 weeks. Ejection fraction remained elevated after 12 weeks in patients with nonischemic HF, but not ischemic HF. There was no difference in treadmill walking times between RT-100 and placebo. 5.
Article Title: Drug and Device News
Article Snippet: Source: Swedish Orphan Biovitrum AB, January 23, 2018 RT-100 AC6 Gene Transfer For Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: Drug and Device News
Article Snippet: Source: Concentric Analgesics, December 7, 2017 RT-100 AC6 for Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer for the treatment of heart failure with reduced ejection fraction.
Injection:Article Title: Drug and Device News
Article Snippet: Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) , Renova Therapeutics , Urocortin hormone , In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less. 10.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) Renova Therapeutics Urocortin hormone In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Ad5.hAC6 (RT-100) , Renova Therapeutics , Gene therapy , In a 56-patient, phase II trial, a single dose of RT-100 increased left ventricular peak and ejection fraction compared with placebo at 4 weeks. Ejection fraction remained elevated after 12 weeks in patients with nonischemic HF, but not ischemic HF. There was no difference in treadmill walking times between RT-100 and placebo. 5.
Article Title: Drug and Device News
Article Snippet: Source: Swedish Orphan Biovitrum AB, January 23, 2018 RT-100 AC6 Gene Transfer For Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: Drug and Device News
Article Snippet: Source: Concentric Analgesics, December 7, 2017 RT-100 AC6 for Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer for the treatment of heart failure with reduced ejection fraction.
Clinical Proteomics:Article Title: Drug and Device News
Article Snippet: Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) , Renova Therapeutics , Urocortin hormone , In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less. 10.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) Renova Therapeutics Urocortin hormone In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Ad5.hAC6 (RT-100) , Renova Therapeutics , Gene therapy , In a 56-patient, phase II trial, a single dose of RT-100 increased left ventricular peak and ejection fraction compared with placebo at 4 weeks. Ejection fraction remained elevated after 12 weeks in patients with nonischemic HF, but not ischemic HF. There was no difference in treadmill walking times between RT-100 and placebo. 5.
Article Title: Drug and Device News
Article Snippet: Source: Swedish Orphan Biovitrum AB, January 23, 2018 RT-100 AC6 Gene Transfer For Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: Drug and Device News
Article Snippet: Source: Concentric Analgesics, December 7, 2017 RT-100 AC6 for Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer for the treatment of heart failure with reduced ejection fraction.
Ex Vivo:Article Title: Drug and Device News
Article Snippet: Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) , Renova Therapeutics , Urocortin hormone , In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less. 10.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) Renova Therapeutics Urocortin hormone In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Ad5.hAC6 (RT-100) , Renova Therapeutics , Gene therapy , In a 56-patient, phase II trial, a single dose of RT-100 increased left ventricular peak and ejection fraction compared with placebo at 4 weeks. Ejection fraction remained elevated after 12 weeks in patients with nonischemic HF, but not ischemic HF. There was no difference in treadmill walking times between RT-100 and placebo. 5.
Article Title: Drug and Device News
Article Snippet: Source: Swedish Orphan Biovitrum AB, January 23, 2018 RT-100 AC6 Gene Transfer For Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: Drug and Device News
Article Snippet: Source: Concentric Analgesics, December 7, 2017 RT-100 AC6 for Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer for the treatment of heart failure with reduced ejection fraction.
Transplantation Assay:Article Title: Drug and Device News
Article Snippet: Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) , Renova Therapeutics , Urocortin hormone , In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less. 10.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) Renova Therapeutics Urocortin hormone In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Ad5.hAC6 (RT-100) , Renova Therapeutics , Gene therapy , In a 56-patient, phase II trial, a single dose of RT-100 increased left ventricular peak and ejection fraction compared with placebo at 4 weeks. Ejection fraction remained elevated after 12 weeks in patients with nonischemic HF, but not ischemic HF. There was no difference in treadmill walking times between RT-100 and placebo. 5.
Article Title: Drug and Device News
Article Snippet: Source: Swedish Orphan Biovitrum AB, January 23, 2018 RT-100 AC6 Gene Transfer For Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: Drug and Device News
Article Snippet: Source: Concentric Analgesics, December 7, 2017 RT-100 AC6 for Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer for the treatment of heart failure with reduced ejection fraction.
Transferring:Article Title: Drug and Device News
Article Snippet: Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) , Renova Therapeutics , Urocortin hormone , In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less. 10.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) Renova Therapeutics Urocortin hormone In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Ad5.hAC6 (RT-100) , Renova Therapeutics , Gene therapy , In a 56-patient, phase II trial, a single dose of RT-100 increased left ventricular peak and ejection fraction compared with placebo at 4 weeks. Ejection fraction remained elevated after 12 weeks in patients with nonischemic HF, but not ischemic HF. There was no difference in treadmill walking times between RT-100 and placebo. 5.
Article Title: Drug and Device News
Article Snippet: Source: Swedish Orphan Biovitrum AB, January 23, 2018 RT-100 AC6 Gene Transfer For Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: Drug and Device News
Article Snippet: Source: Concentric Analgesics, December 7, 2017 RT-100 AC6 for Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer for the treatment of heart failure with reduced ejection fraction.
Plasmid Preparation:Article Title: Drug and Device News
Article Snippet: Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) , Renova Therapeutics , Urocortin hormone , In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less. 10.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) Renova Therapeutics Urocortin hormone In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Ad5.hAC6 (RT-100) , Renova Therapeutics , Gene therapy , In a 56-patient, phase II trial, a single dose of RT-100 increased left ventricular peak and ejection fraction compared with placebo at 4 weeks. Ejection fraction remained elevated after 12 weeks in patients with nonischemic HF, but not ischemic HF. There was no difference in treadmill walking times between RT-100 and placebo. 5.
Article Title: Drug and Device News
Article Snippet: Source: Swedish Orphan Biovitrum AB, January 23, 2018 RT-100 AC6 Gene Transfer For Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: Drug and Device News
Article Snippet: Source: Concentric Analgesics, December 7, 2017 RT-100 AC6 for Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer for the treatment of heart failure with reduced ejection fraction.
Functional Assay:Article Title: Drug and Device News
Article Snippet: Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) , Renova Therapeutics , Urocortin hormone , In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less. 10.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) Renova Therapeutics Urocortin hormone In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Ad5.hAC6 (RT-100) , Renova Therapeutics , Gene therapy , In a 56-patient, phase II trial, a single dose of RT-100 increased left ventricular peak and ejection fraction compared with placebo at 4 weeks. Ejection fraction remained elevated after 12 weeks in patients with nonischemic HF, but not ischemic HF. There was no difference in treadmill walking times between RT-100 and placebo. 5.
Article Title: Drug and Device News
Article Snippet: Source: Swedish Orphan Biovitrum AB, January 23, 2018 RT-100 AC6 Gene Transfer For Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: Drug and Device News
Article Snippet: Source: Concentric Analgesics, December 7, 2017 RT-100 AC6 for Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer for the treatment of heart failure with reduced ejection fraction.
Virus:Article Title: Drug and Device News
Article Snippet: Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) , Renova Therapeutics , Urocortin hormone , In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less. 10.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) Renova Therapeutics Urocortin hormone In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Ad5.hAC6 (RT-100) , Renova Therapeutics , Gene therapy , In a 56-patient, phase II trial, a single dose of RT-100 increased left ventricular peak and ejection fraction compared with placebo at 4 weeks. Ejection fraction remained elevated after 12 weeks in patients with nonischemic HF, but not ischemic HF. There was no difference in treadmill walking times between RT-100 and placebo. 5.
Article Title: Drug and Device News
Article Snippet: Source: Swedish Orphan Biovitrum AB, January 23, 2018 RT-100 AC6 Gene Transfer For Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: Drug and Device News
Article Snippet: Source: Concentric Analgesics, December 7, 2017 RT-100 AC6 for Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer for the treatment of heart failure with reduced ejection fraction.
Variant Assay:Article Title: Drug and Device News
Article Snippet: Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) , Renova Therapeutics , Urocortin hormone , In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less. 10.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) Renova Therapeutics Urocortin hormone In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Ad5.hAC6 (RT-100) , Renova Therapeutics , Gene therapy , In a 56-patient, phase II trial, a single dose of RT-100 increased left ventricular peak and ejection fraction compared with placebo at 4 weeks. Ejection fraction remained elevated after 12 weeks in patients with nonischemic HF, but not ischemic HF. There was no difference in treadmill walking times between RT-100 and placebo. 5.
Article Title: Drug and Device News
Article Snippet: Source: Swedish Orphan Biovitrum AB, January 23, 2018 RT-100 AC6 Gene Transfer For Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: Drug and Device News
Article Snippet: Source: Concentric Analgesics, December 7, 2017 RT-100 AC6 for Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer for the treatment of heart failure with reduced ejection fraction.
Coagulation:Article Title: Drug and Device News
Article Snippet: Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) , Renova Therapeutics , Urocortin hormone , In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less. 10.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) Renova Therapeutics Urocortin hormone In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Ad5.hAC6 (RT-100) , Renova Therapeutics , Gene therapy , In a 56-patient, phase II trial, a single dose of RT-100 increased left ventricular peak and ejection fraction compared with placebo at 4 weeks. Ejection fraction remained elevated after 12 weeks in patients with nonischemic HF, but not ischemic HF. There was no difference in treadmill walking times between RT-100 and placebo. 5.
Article Title: Drug and Device News
Article Snippet: Source: Swedish Orphan Biovitrum AB, January 23, 2018 RT-100 AC6 Gene Transfer For Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: Drug and Device News
Article Snippet: Source: Concentric Analgesics, December 7, 2017 RT-100 AC6 for Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer for the treatment of heart failure with reduced ejection fraction.
Recombinant:Article Title: Drug and Device News
Article Snippet: Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) , Renova Therapeutics , Urocortin hormone , In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less. 10.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) Renova Therapeutics Urocortin hormone In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Ad5.hAC6 (RT-100) , Renova Therapeutics , Gene therapy , In a 56-patient, phase II trial, a single dose of RT-100 increased left ventricular peak and ejection fraction compared with placebo at 4 weeks. Ejection fraction remained elevated after 12 weeks in patients with nonischemic HF, but not ischemic HF. There was no difference in treadmill walking times between RT-100 and placebo. 5.
Article Title: Drug and Device News
Article Snippet: Source: Swedish Orphan Biovitrum AB, January 23, 2018 RT-100 AC6 Gene Transfer For Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: Drug and Device News
Article Snippet: Source: Concentric Analgesics, December 7, 2017 RT-100 AC6 for Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer for the treatment of heart failure with reduced ejection fraction.
Retroviral:Article Title: Drug and Device News
Article Snippet: Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) , Renova Therapeutics , Urocortin hormone , In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less. 10.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) Renova Therapeutics Urocortin hormone In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Ad5.hAC6 (RT-100) , Renova Therapeutics , Gene therapy , In a 56-patient, phase II trial, a single dose of RT-100 increased left ventricular peak and ejection fraction compared with placebo at 4 weeks. Ejection fraction remained elevated after 12 weeks in patients with nonischemic HF, but not ischemic HF. There was no difference in treadmill walking times between RT-100 and placebo. 5.
Article Title: Drug and Device News
Article Snippet: Source: Swedish Orphan Biovitrum AB, January 23, 2018 RT-100 AC6 Gene Transfer For Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: Drug and Device News
Article Snippet: Source: Concentric Analgesics, December 7, 2017 RT-100 AC6 for Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer for the treatment of heart failure with reduced ejection fraction.
Infection:Article Title: Drug and Device News
Article Snippet: Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) , Renova Therapeutics , Urocortin hormone , In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less. 10.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) Renova Therapeutics Urocortin hormone In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Ad5.hAC6 (RT-100) , Renova Therapeutics , Gene therapy , In a 56-patient, phase II trial, a single dose of RT-100 increased left ventricular peak and ejection fraction compared with placebo at 4 weeks. Ejection fraction remained elevated after 12 weeks in patients with nonischemic HF, but not ischemic HF. There was no difference in treadmill walking times between RT-100 and placebo. 5.
Article Title: Drug and Device News
Article Snippet: Source: Swedish Orphan Biovitrum AB, January 23, 2018 RT-100 AC6 Gene Transfer For Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: Drug and Device News
Article Snippet: Source: Concentric Analgesics, December 7, 2017 RT-100 AC6 for Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer for the treatment of heart failure with reduced ejection fraction.
Mutagenesis:Article Title: Drug and Device News
Article Snippet: Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) , Renova Therapeutics , Urocortin hormone , In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less. 10.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Stresscopin (RT-400) Renova Therapeutics Urocortin hormone In a 62-patient, phase II trial, stresscopin increased the cardiac index and decreased systemic vascular resistance compared with placebo in stable HF patients with a left ventricular ejection fraction of 35% or less.
Article Title: New Medications in the Treatment of Acute Decompensated Heart Failure
Article Snippet: Ad5.hAC6 (RT-100) , Renova Therapeutics , Gene therapy , In a 56-patient, phase II trial, a single dose of RT-100 increased left ventricular peak and ejection fraction compared with placebo at 4 weeks. Ejection fraction remained elevated after 12 weeks in patients with nonischemic HF, but not ischemic HF. There was no difference in treadmill walking times between RT-100 and placebo. 5.
Article Title: Drug and Device News
Article Snippet: Source: Swedish Orphan Biovitrum AB, January 23, 2018 RT-100 AC6 Gene Transfer For Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer (Ad5.hAC6) for the treatment of heart failure (HF) with reduced ejection fraction.
Article Title: Drug and Device News
Article Snippet: Source: Concentric Analgesics, December 7, 2017 RT-100 AC6 for Heart Failure Renova Therapeutics has been granted a fast-track designation for RT-100 AC6 gene transfer for the treatment of heart failure with reduced ejection fraction.
|
